Ex pharma execs first to be charged in generic drug pricing case

Former Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide from 2013 and 2015. Other drug makers have reportedly received subpoenas as a part of the U.S. Justice Dept. probe. Bloomberg News reported that Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA), and Endo International’s Par subsidiary are among the companies being investigated by federal authorities for co-conspirating to fix the market for generic drugs. Get the full story at our sister site, Drug Delivery Business News. The post Ex pharma execs first to be charged in generic drug pricing case appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Dept. of Justice (DOJ) Heritage Pharmaceuticals Mylan Teva Pharmaceuticals Source Type: news